Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease.

Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last  decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents that patients can self-administer  subcutaneously after collecting them from the pharmacy department.

Complementary medicine use in cancer patients receiving intravenous antineoplastic treatment.

Objective: Complementary and alternative medicine (CAM) use has grown considerably, although there is little research on the topic in Spain. The aim of this study was to determine the prevalence of complementary medicine use in adult cancer patients at the same time as they were receiving conventional treatment in a Spanish referral cancer centre.

Method: An observational, descriptive, cross-sectional study was conducted in the Ambulatory Treatment Unit during 2 consecutive weeks in March 2015.